Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer

URN:NBN:SI:doc-49OTGCCW2021Grašič-Kuhar, CvetkaPrivšek, Ninadocuments/doc/4/URN_NBN_SI_doc-49OTGCCW_001.pdfdocuments/doc/4/URN_NBN_SI_doc-49OTGCCW_001.txt225articlestr. 48-531408-174188612099URN:NBN:SI:doc-49OTGCCWslvOnkološki inštitut LjubljanaOnkologija (Ljubljana)BYabemaciklibneželeni učinkipalbociklibribociklibzaviralci CDK4/6Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancerUčinkovitost in najpogostejši neželeni učinki zdravljenja z zaviralci od ciklina odvisnih kinaz 4 in 6 (CDK 4/6) pri metastatskem raku dojke